Development of an Ultra-Sensitive Human Cardiac Troponin I Sandwich ELISA

Key Takeaways

• BOLD technology increases ELISA sensitivity 180‑fold
• Detection limit lowered to 0.07 pg/mL
• Integrates with existing workflows, no new equipment
• Enables earlier cardiotoxicity detection in drug development
• Benefits cardiovascular researchers and biomarker discovery teams

Summary

Exazym®'s BOLD amplification technology boosts the sensitivity of a human cardiac troponin I sandwich ELISA by 180‑fold, lowering the detection limit to 0.07 pg/mL. The webinar presented by Cavidi’s Peter Stenlund shows how the method integrates into standard ELISA workflows with minimal protocol changes and no new equipment. This ultra‑sensitive assay targets low‑abundance cTnI detection for cardiac research, drug safety monitoring, and biomarker discovery. The approach promises earlier identification of heart injury and cardiotoxic effects in pre‑clinical and clinical settings.

Pulse Analysis

Cardiac troponin I (cTnI) remains the definitive biomarker for myocardial injury, guiding both clinical decision‑making and pre‑clinical safety studies. Traditional sandwich ELISAs, while widely used, often struggle to detect the sub‑picogram concentrations that signal the earliest phases of cardiac stress, limiting their utility in high‑throughput drug‑toxicity screens and biomarker discovery projects. As pharmaceutical pipelines increasingly demand sensitive, quantitative readouts for low‑abundance proteins, the market has been searching for a solution that delivers laboratory‑grade precision without the cost and complexity of mass‑spectrometry or novel instrumentation.

The BOLD (Binding Oligo Ladder Detection) platform introduced by Exazym® addresses this gap by attaching a ladder of oligonucleotides to detection antibodies, creating a cascade that amplifies the enzymatic signal up to 180‑fold. In Cavidi’s recent webinar, Peter Stenlund demonstrated that the modified sandwich ELISA pushes the cTnI limit of detection down to 0.07 pg/mL, a level previously attainable only with specialized platforms. Importantly, the workflow requires only minor protocol tweaks—adjusted antibody concentrations and a brief incubation step—allowing laboratories to retain existing plate readers and automation setups.

The immediate impact is twofold: drug developers can identify cardiotoxic liabilities weeks earlier, reducing late‑stage attrition, while academic researchers gain access to ultra‑low‑level cTnI data that can uncover new pathophysiological insights. CROs and diagnostic firms are also poised to differentiate their service offerings by marketing ultra‑sensitive ELISA panels that meet regulatory expectations for early‑risk detection. As the industry moves toward precision medicine, technologies like BOLD that combine high sensitivity with low implementation barriers are likely to become standard components of the biomarker toolbox.